AHA 2021 Two phase I studies report the safety and effectiveness of MK-0616, a new oral PCSK9 inhibitor. MK-0616 lowered free PCSK9 in the blood by ≥90% and reduced LDL-c by ~65% after 14 days of treatment, compared to baseline.

Treatment with the PCSK9 inhibitor evolocumab in high CV risk patients reduced the risk of acute arterial events across all vascular territories, as shown in a post hoc analysis of FOURIER.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

An exploratory analysis of FOURIER showed that lowering of LDL-c by evolocumab below 40 mg/dL resulted in continued reduction of MACE in ASCVD patients.

The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.

ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

ESC 2021 The Nature-PCSK9 trial, a naturally randomized target trial, showed a stepwise increase in the proportional reduction in lifetime risk of CV events with each earlier decade that LDL-c lowering was started by inhibiting PCSK9 with one-yearly dose of siRNA.

ESC 2021 Imaging findings from the HUYGENS study showed that increase in minimum fibrous cap thickness and decrease in the maximum lipid arc was greater after 12 months of evolocumab compared to placebo post-ACS.

Physician reminders for recommended LLT led to an increase in the proportion of patients with FH and/or CVD achieving LDL-c treatment goals. However, treatment inertia exists in patients with FH, including those with established CVD.

This prospective registry study in the US showed that only 17.1% of patients with ASCVD on LLT had their therapy intensified over the next 2 years. Only 31.7% of patients achieved LDL-c levels <70mg/dL at 2 years.

EAS 2021 An interim-analysis of the HEYMANS study showed that the majority of FH (both HeFH and HoFH) patients have a history of CV events and comorbidities. Initiation of evolocumab in these patients resulted in reduced LDL-c levels, maintained throughout the study.